TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rockwell Med ( (RMTI) ) has shared an update.
On November 17, 2025, Andrea Heslin Smiley resigned from the Board of Directors of Rockwell Medical, Inc., and was replaced by Joseph H. Dawson as a Class II director. Mr. Dawson, an independent consultant with a background in medical corporations, will serve until the 2026 Annual Meeting of Stockholders and has been appointed to the Nominating and Corporate Governance Committee. He will receive a pro-rated annual cash retainer and equity awards, which will vest in 2026, as part of his compensation.
The most recent analyst rating on (RMTI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Rockwell Med stock, see the RMTI Stock Forecast page.
Spark’s Take on RMTI Stock
According to Spark, TipRanks’ AI Analyst, RMTI is a Neutral.
Rockwell Med’s overall stock score is primarily impacted by its financial struggles, including declining revenues and profitability issues. Technical analysis indicates bearish momentum, and valuation metrics reflect ongoing losses. While the earnings call provided some positive developments, significant challenges remain, particularly with declining sales and customer transitions.
To see Spark’s full report on RMTI stock, click here.
More about Rockwell Med
Average Trading Volume: 1,487,770
Technical Sentiment Signal: Sell
Current Market Cap: $36.22M
For an in-depth examination of RMTI stock, go to TipRanks’ Overview page.